Summary
JM Financial has maintained its 'Buy' rating on Metropolis Healthcare, calling it the 'best-value diagnostic stock' with a target price of Rs 734, implying a 27.2% upside. The brokerage cites attractive valuations, network expansion, and improving margins as key drivers.